VanEck Dividend ETF's Record Run Powered by Defensive Shift

A powerful rotation out of growth stocks has propelled income-focused funds to the front of the pack this year. The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF (TDIV) is a prime beneficiary, with its strategy of targeting the world's most reliable dividend payers delivering standout returns. The fund's underlying index surged 15.1% in the first quarter of 2026, marking its strongest quarterly performance since late 2022.

This momentum has pushed the ETF's price to €52.24, a mere 1.2% below its 52-week high of €53.10. Since January, the fund has advanced roughly eight percent, while its total return over the past twelve months, including dividends, approaches 28 percent.

The fund's success is rooted in a stringent selection process. It physically replicates the Morningstar Developed Markets Large Cap Dividend Leaders Index, which identifies 100 top dividend-paying companies globally. Rules are strict: payout ratios cannot exceed 75% of earnings, and the current dividend must be higher than it was five years ago. An additional ESG filter screens out controversial business models. The approach has yielded consistent income, with the dividend growing at an average annual clip of nearly 17 percent. The ETF currently offers a dividend yield of 3.83%.

Should investors sell immediately? Or is it worth buying VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF?

Sector allocation has been a key driver. The portfolio is dominated by defensive areas, with financials accounting for about 32%, energy nearly 18%, and healthcare over 15%. This tilt has perfectly captured the recent market shift. As geopolitical tensions weighed on technology shares, energy stocks like top holdings Exxon Mobil and Chevron rallied. Verizon, another major position, jumped 25.6% in the quarter alone, providing a significant boost.

The fund's weighting methodology, which is based on absolute dividend paid rather than market capitalization, inherently favors mature, cash-generative companies. Other significant holdings include Pfizer, Roche, and Nestlé. However, risks persist. Persistent inflation could delay interest rate cuts, pressuring interest-sensitive financial stocks. Analysts also forecast a nearly ten percent earnings decline in the healthcare sector, which would impact giants like Roche.

Investor appetite for this strategy is clear. U.S. dividend funds recorded net inflows of approximately $24 billion in Q1 2026—the strongest first quarter in four years, reversing a three-year outflow trend. Assets under management for the VanEck ETF have swelled to €7.4 billion.

With a price-to-earnings ratio of just under 13, the fund remains attractive to value-oriented investors. The next test arrives in June, when the ETF is scheduled to make its regular quarterly distribution—its last payout was €0.21 per share, bringing the trailing twelve-month total to €1.74. This period also coincides with the index's semi-annual rebalancing. How the portfolio adjusts, alongside upcoming earnings from key cyclical sectors, will determine if this dividend leader can maintain its advantage.

Ad

VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock: New Analysis - 22 April

Fresh VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF analysis...

en | NL0011683594 | VANECK | boerse | 69233200 |